Last reviewed 2026-04-23 · How we verify

wIPV

WIPV is a small molecule targeting the SARS-CoV-2 main protease.

WIPV is a small molecule targeting the SARS-CoV-2 main protease. Used for Treatment of COVID-19.

At a glance

Mechanism of action

WIPV works by inhibiting the main protease of SARS-CoV-2, which is essential for the viral replication. This inhibition prevents the virus from replicating and spreading within the host. As a result, WIPV has antiviral properties.

Approved indications

• Treatment of COVID-19

Common side effects

• Nausea
• Headache
• Diarrhea

Key clinical trials

• Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
• Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
• A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
• Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine (PHASE3)
• Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization (NA)
• A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (PHASE3)
• A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• wIPV CI brief — competitive landscape report
• wIPV updates RSS · CI watch RSS
• Beijing Minhai Biotechnology Co., Ltd portfolio CI